Appendices
Operator matrix, market sizing quick-reference, key figures index, compound reference, and methodology notes.
Reference
40+
Operators in the full matrix
15
Market sizing rows tracked
12
Frontier compounds referenced
Appendix A — Operator Matrix (Full)
Table · Operator Matrix (40 operators)
40 shown
| Operator | Archetype | Clinical ↓ | Experience | Stage | Region |
|---|---|---|---|---|---|
| Human Longevity Inc. | Premium Longevity Clinic | 9.5 | 6.5 | mature | U.S. |
| Lanserhof Tegernsee | European Longevity | 9.3 | 8.5 | mature | Germany |
| Fountain Life | Premium Longevity Clinic | 9.0 | 7.5 | growth | U.S. |
| Neko Health | Premium Longevity Clinic | 8.5 | 7.0 | growth | Sweden / U.S. |
| Grail Galleri | DTC Diagnostics | 8.5 | 6.0 | public | U.S. |
| Clinique La Prairie | European Longevity | 8.5 | 9.0 | mature | Switzerland |
| Prenuvo | DTC Diagnostics | 8.0 | 7.5 | growth | U.S. / Canada |
| Paracelsus Clinic | European Longevity | 8.0 | 7.5 | mature | Switzerland |
| Function Health | DTC Diagnostics | 7.5 | 8.5 | growth | U.S. |
| Hone Health | Telehealth Functional | 7.5 | 7.0 | growth | U.S. |
| Chenot Palace Weggis | European Longevity | 7.5 | 9.0 | mature | Switzerland |
| SHA Wellness Clinic | European Longevity | 7.5 | 9.0 | mature | Spain |
| Velvaere (Park City) | Longevity Residence | 7.5 | 9.0 | seed | U.S. |
| Levels | CGM / Interpretation | 7.5 | 7.5 | growth | U.S. |
| Oura Ring | Wearable | 7.5 | 8.5 | mature | Finland / U.S. |
| InsideTracker | DTC Diagnostics | 7.0 | 7.0 | mature | U.S. |
| TruDiagnostic | DTC Diagnostics | 7.0 | 6.0 | growth | U.S. |
| Hippocrates Wellness | Integrated Health Campus | 7.0 | 8.5 | mature | U.S. |
| Ways2Well | Telehealth Functional | 7.0 | 6.5 | growth | U.S. |
| Tri Vananda | Longevity Residence | 7.0 | 9.0 | seed | Thailand |
| The Estate | Longevity Residence | 7.0 | 8.5 | seed | U.S. |
| Blueprint (Bryan Johnson) | Protocol Brand | 7.0 | 5.5 | growth | U.S. |
| Blokes / Joi | Telehealth Functional | 6.5 | 6.5 | growth | U.S. |
| Ro (Roman / Rory) | Telehealth Functional | 6.5 | 7.5 | mature | U.S. |
| Canyon Ranch Austin | Longevity Residence | 6.5 | 9.0 | seed | U.S. |
| Sensei Lānaʻi | Athletic Country Club | 6.5 | 8.5 | growth | U.S. |
| Whoop | Wearable | 6.5 | 7.5 | mature | U.S. |
| Next Health | Franchised Biohacking | 6.0 | 7.0 | growth | U.S. |
| Hims & Hers | Telehealth Functional | 6.0 | 7.5 | public | U.S. |
| Life Time Health | Athletic Country Club | 6.0 | 7.5 | public | U.S. |
| Canyon Ranch | Legacy Softcare | 5.5 | 9.0 | mature | U.S. |
| Equinox Hotels | Athletic Country Club | 5.5 | 8.0 | growth | U.S. |
| Golden Door | Legacy Softcare | 5.0 | 9.0 | mature | U.S. |
| Upgrade Labs | Franchised Biohacking | 5.0 | 6.5 | growth | U.S. |
| Restore Hyper Wellness | Franchised Biohacking | 5.0 | 6.5 | mature | U.S. |
| Miraval | Legacy Softcare | 4.0 | 9.5 | mature | U.S. |
| Rancho La Puerta | Legacy Softcare | 4.0 | 9.5 | mature | Mexico |
| Kripalu | Legacy Softcare | 3.5 | 9.0 | mature | U.S. |
| Esalen | Legacy Softcare | 3.0 | 9.0 | mature | U.S. |
| Omega Institute | Legacy Softcare | 3.0 | 8.5 | mature | U.S. |
Scored across two dimensions — Clinical Credibility (0–10) and Consumer Experience (0–10) — synthesized from industry research, operator disclosures, and expert assessment 2024–2026. Used to illustrate the Hardcare/Softcare bifurcation articulated in Part IV.
Hardcare Pole (Clinical Credibility Leaders)
| Operator | Country | Clinical | Experience | Positioning |
|---|---|---|---|---|
| Lanserhof Tegernsee | Germany | 9.3 | 8.5 | Premier integrated medical-hospitality |
| Lanserhof Lans | Austria | 9.2 | 8.3 | Clinical-forward Mayr medicine |
| Lanserhof Sylt | Germany | 9.1 | 8.4 | Island clinical wellness |
| Clinique La Prairie Montreux | Switzerland | 9.0 | 9.0 | The global benchmark |
| TrueNorth Health Center | USA | 9.0 | 5.5 | Medically supervised water fasting |
| Buchinger Wilhelmi | Germany | 8.8 | 7.8 | Therapeutic fasting pioneer |
| SHA Wellness Alicante | Spain | 8.6 | 8.8 | East-West integrated medical |
| SHA Wellness Quintana Roo | Mexico | 8.6 | 8.9 | East-West integrated, Mayan |
| Chenot Palace Weggis | Switzerland | 8.5 | 8.6 | Detox and chrono-nutrition |
| VIVAMAYR Altaussee | Austria | 8.5 | 8.2 | Modernized Mayr medicine |
| Palace Merano | Italy | 8.4 | 8.5 | Alpine medical wellness |
| Grand Resort Bad Ragaz | Switzerland | 8.4 | 8.3 | Medical-wellness integration |
| Fountain Life | USA (multi) | 8.3 | 8.0 | U.S. premium longevity anchor |
| Human Longevity Inc. | USA | 8.2 | 7.8 | Genomics + imaging pioneer |
| Mayo Executive Health | USA | 8.2 | 7.5 | Institutional executive medicine |
| Cleveland Clinic Functional | USA | 8.1 | 7.6 | Institutional functional medicine |
| Canyon Ranch Austin | USA | 8.0 | 8.5 | Residential + medical integration |
| Neko Health | Sweden/UK/US | 8.0 | 8.5 | Tech-driven full-body scan |
| Mayr Clinic | Austria | 7.9 | 8.0 | Original Mayr medicine |
| Love.Life | USA | 7.8 | 8.4 | Integrated 45K sq ft campus |
| Cooper Clinic Dallas | USA | 7.8 | 7.5 | Preventive medicine legacy |
| Kamalaya | Thailand | 7.8 | 8.8 | Asian integrative |
| Prenuvo | USA (multi) | 7.6 | 7.8 | Full-body MRI scale |
Softcare Pole (Experience / Emotional Leaders)
| Operator | Country | Clinical | Experience | Positioning |
|---|---|---|---|---|
| Golden Door | USA | 5.0 | 9.3 | Emotional restoration excellence |
| Ananda in the Himalayas | India | 5.2 | 9.0 | Ayurvedic-spiritual benchmark |
| Aman Wellness (network) | Multi | 5.0 | 8.6 | Hospitality-first luxury |
| Miraval Tucson | USA | 5.5 | 8.6 | Softcare U.S. leader |
| Miraval Austin | USA | 5.5 | 8.6 | Texas softcare |
| Miraval Berkshires | USA | 5.5 | 8.6 | Northeast softcare |
| Canyon Ranch Tucson | USA | 7.5 | 8.5 | Legacy U.S. wellness |
| Canyon Ranch Lenox | USA | 7.4 | 8.5 | New England legacy |
| Sensei Lanai | USA (HI) | 7.0 | 8.7 | Ellison premium longevity |
| The Ranch Malibu | USA | 6.8 | 8.2 | Intensive hiking/detox |
| Six Senses Places | Multi | 5.5 | 8.5 | Asian-inspired hospitality-wellness |
| Banyan Tree Veya | Multi | 5.2 | 8.3 | Asian hospitality wellness |
| Aurum at Six Senses | Multi | 6.5 | 8.2 | Longevity programming |
| Rythmia Life Advancement | Costa Rica | 6.8 | 8.5 | Medically-licensed ayahuasca |
| Sanctuary Tulum | Mexico | 6.5 | 8.7 | Luxury plant medicine |
Strategic Middle / Mixed Positioning
| Operator | Country | Clinical | Experience | Positioning |
|---|---|---|---|---|
| Life Time / MIORA | USA | 6.8 | 7.5 | Athletic club + longevity |
| Equinox | USA (multi) | 5.8 | 8.0 | Urban premium fitness |
| Next Health | USA (franchise) | 6.5 | 7.0 | Retail longevity franchise |
| Upgrade Labs | USA (franchise) | 6.5 | 7.2 | Biohacking gym franchise |
| Restore Hyper Wellness | USA (franchise) | 5.8 | 7.0 | Retail recovery franchise |
| Function Health | USA (digital) | 7.5 | 7.8 | Scalable DTC diagnostics |
| Parsley Health | USA (digital) | 7.2 | 7.5 | Telehealth functional medicine |
| Hippocrates Wellness | USA | 5.3 | 5.6 | Mid-market exposure |
| Pritikin Longevity Center | USA | 6.2 | 6.8 | Legacy lifestyle medicine |
| Hilton Head Health | USA | 6.0 | 7.2 | Legacy weight management |
Longevity Residences (Non-Comparable Scoring)
| Operator | Country | Status | Clinical Partner |
|---|---|---|---|
| Velvaere (Park City) | USA | Active | Fountain Life |
| Tri Vananda (Phuket) | Thailand | Active | Clinique La Prairie |
| Canyon Ranch Austin | USA | Active 2024–2026 | Canyon Ranch programming |
| The Estate | Multi | Developing | Variable |
| Elysium Fields (Gold Coast) | Australia | Planned | TBD |
| Prana Del Mar (Cabo) | Mexico | Closing June 10 2026 | Kaleidoscope Ventures |
Appendix B — Quick-Reference Market Sizing Data
Table · Market Sizing Quick-Reference
| Category | Current ↓ | Projected | CAGR | Source |
|---|---|---|---|---|
| Global Wellness Economy | $6.8T 2024 | $9.8T 2029 | 7.6% | GWI |
| U.S. Wellness Economy | $2.1T 2024 | $2.9T 2029 | 6.7% | GWI |
| Wellness Real Estate (Global) | $548B 2024 | $1.1T 2029 | 15.2% | GWI |
| U.S. Wellness (narrow, McKinsey) | $500B 2024 | $640B 2029 | 4–5% | McKinsey |
| Menopause Market (Global) | $325B 2024 | $600B 2030 | 10.8% | Fortune Bus. |
| Peptide Therapeutics (Global) | $140B 2025 | $295B 2033 | 9.8% | Market Data |
| Femtech (Global) | $63B 2025 | $267B 2035 | 15.5% | Precedence |
| U.S. Complementary & Alternative Medicine | $53B 2025 | $376B 2033 | 27.8% | Grand View |
| Wearable Health Devices (U.S.) | $48B 2025 | $115B 2030 | 19.1% | Rock Health |
| Stem Cell Therapy (Global) | $15B 2025 | $48B 2032 | 18.5% | Market Research |
| Psychedelic Drugs (Global) | $8.50B 2026 | $26B 2034 | 15.1% | Data Bridge |
| Hormone Optimization (U.S., DTC) | $3.20B 2025 | $8.90B 2030 | 22.7% | Industry est. |
| Full-Body Imaging (Consumer) | $2.10B 2025 | $9.80B 2032 | 24.6% | Industry est. |
| Direct Primary Care (U.S.) | $1.20B 2025 | $4.80B 2030 | 32.1% | DPC Coalition |
| Bio-Age Testing (Global) | $800M 2025 | $4.20B 2032 | 26.1% | Industry est. |
Global Wellness Economy (GWI Broad Definition)
- 2019: $4.9T
- 2020: $4.5T (COVID compression)
- 2022: $5.6T
- 2023: $6.3T
- 2024: $6.8T (7.9% YoY)
- 2029 projected: $9.8T (7.6% CAGR)
U.S. Wellness Economy
- GWI broad definition: $2.1T (32% of global)
- McKinsey narrow consumer spend: ~$500B (growing 4–5% annually)
- Per capita: $5,000–$6,000+ (vs. $831 global average)
- Consumer priority: 84% rank wellness top or important (McKinsey)
Fastest-Growing Sub-Sectors Through 2029
- CAM (US): 27.8% CAGR → $52.78B (2025) → $375.51B (2033)
- Biohacking (Global): 19.0% CAGR → $216B by 2035
- Femtech: 15.5% CAGR → $63B (2025) → $267B (2035)
- Wellness Real Estate: 15.2% CAGR → $548B (2024) → $1.1T (2029)
- Psychedelic Drugs: $8.5B (2026) → $26B (2034)
- Traditional & Complementary Medicine: 10.8% CAGR
- Mental Wellness: 10.1% CAGR
- Thermal/Mineral Springs: 10.0% CAGR
- Wellness Tourism: 9.1% CAGR
- Personalized Medicine: 9.3% CAGR
Specific Category Sizes
- Narrow "longevity economy": $610B by 2026 (Clinique La Prairie analysis)
- Anti-aging consumer market: $85B (2025) → $120B+ (2030) at 7% CAGR (Gabelli)
- Nutraceuticals/Supplements (Global): $416B in 2026
- Peptide therapeutics: $140B (2025) → $295B (2033)
- Longevity biotech (consumer-facing): $27B+ globally (2025) → $67B+ (2035)
- Menopause-specific: $600B by 2030
- Psychedelic drugs: $8.5B (2026) → $26B (2034)
- Biological age testing (consumer): ~$500M (2025) → $2B+ (2030)
- U.S. BHRT and hormone optimization: $10–15B annual (growing 12–15%)
Comparative Scale
- U.S. wellness economy (GWI): $2.1T
- U.S. pharmaceutical market: ~$650B
- U.S. hospital system: ~$1.4T
- U.S. health insurance: ~$1.5T
- U.S. wellness already exceeds U.S. pharma
Institutional Trust (2023–2026)
- Gallup: only 33% believe pharma provides good care; 70%+ disapprove
- Edelman: U.S. pharma trust dropped 51% → 38% (-13 pts)
- CDC favorability: +62 (March 2020) → +38 (September 2025), a 24-point drop
- 76.4% of U.S. adults have ≥1 chronic condition (CDC 2023)
- 51.4% have multiple chronic conditions
Exit-from-Allopathy Quantification
- "Fully exited" (DPC + concierge + longevity memberships): 4–6 million adults (1.5–2%)
- "Substantially exited" (regular alternative use): 65–95 million adults (25–36%)
- "Philosophically aligned" (MAHA-supportive): 100–130 million adults (38–50%)
- DPC practices: ~2,500–2,700 nationally (grew 241% 2017–2021)
- HSA eligibility for DPC: up to $150/mo individual, $300/mo family (Jan 2026)
MAHA Polling Snapshot
- 38% of U.S. parents identify as MAHA (KFF/WaPo, Oct 2025)
- 39% of voters support MAHA goals; only 14% identify (Data for Progress, April 2026)
- 52% say admin "hasn't done enough" on MAHA agenda (Politico, April 2026)
- 15–20% are intense supporters (Navigator)
Wearable Penetration
- 53% of Americans own a wearable (Rock Health 2024)
- 54% track at least one health metric digitally
- Oura Ring: 3M+ lifetime units, $5B+ valuation
- Whoop: $3.6B peak valuation
- 76% of U.S. adults take a supplement daily (2025 record)
Longevity Capital (Selected)
- Altos Labs: $3B+ founding capital (Bezos, Milner)
- Retro Biosciences: $1.2B (Altman)
- NewLimit: $280M+ cumulative (Armstrong)
- Hevolution Foundation: $1B+ (Saudi Arabia)
- BOLD Capital (Diamandis): $600M+ deployed
- Longevity Fund (Deming): $37M AUM, top-decile DPI
- age1 (Deming + Colville): $50M+ fund
- Kizoo (Greve): European longevity focus
- Longevity Vision Fund (Sergey Young): European capital
- XPRIZE Healthspan: $101M prize pool
Appendix C — Key Figures, Conferences, and Platforms
The People — By Tributary
Tributary One — Ancient Recovery (selected): Deepak Chopra · Vasant Lad · John Douillard · Andrew Weil · Tieraona Low Dog · Aviva Romm · Mimi Guarneri · Sri Sri Ravi Shankar · Rangan Chatterjee · Dennis McKenna · Paul Stamets · Michael Pollan · Rick Doblin · Roland Griffiths (legacy) · Matthew Johnson · Robin Carhart-Harris · David Nutt · Gabor Maté · Ram Dass (legacy) · Thich Nhat Hanh (legacy) · Jon Kabat-Zinn
Tributary Two — Scientific Frontier (selected): Cynthia Kenyon · David Sinclair · George Church · Aubrey de Grey · Judith Campisi (legacy) · Matt Kaeberlein · Nir Barzilai · Valter Longo · Morgan Levine · Eric Verdin · Steve Horvath · Shinya Yamanaka · Juan Carlos Izpisúa Belmonte · Vadim Gladyshev · Brian Kennedy · Richard Miller · Steve Austad · Lei Cai · João Pedro de Magalhães · Linda Partridge · Maria Blasco · Shin-ichiro Imai · Lei Wu · Vera Gorbunova · Andrei Seluanov · Jennifer Garrison · Daisy Robinton · Laura Deming · Alex Colville · Alex Zhavoronkov · Joon Yun · Jim Mellon · Sergey Young · Celine Halioua · Nathaniel David
Tributary Three — Sovereign Individual (selected): Dave Asprey · Bryan Johnson · Peter Diamandis · Peter Attia · Mark Hyman · Craig Koniver · William Seeds · Gabrielle Lyon · Edward Lee · Neil Rouzier · Kent Holtorf · Mark Gordon · Gabrielle Lyon · Molly Maloof · Mary Claire Haver · Heather Hirsch · Amy Shah · Sara Gottfried · Jaclyn Estima · Stacy Sims · Kelly Brogan · Dom D'Agostino · Rhonda Patrick · Chris Masterjohn · William Li · David Perlmutter · Paul Saladino · Max Lugavere · Will Cole · Ben Greenfield · Tim Ferriss · Kelly Starrett · Laird Hamilton + Gabby Reece · Wim Hof · Aubrey Marcus · Shawn Stevenson · Dan Go · Luke Storey · Gary Brecka · Dave Pascoe · Steven Kotler · Jamie Wheal · Andrew Huberman · Joe Rogan · Lex Fridman
Conferences and Summits
- Biohacking Conference (Asprey, annual since 2014)
- A4M World Congress (American Academy of Anti-Aging Medicine)
- HLTH Conference (broad digital health + wellness)
- RAADfest (Revolution Against Aging and Death)
- Longevity Investors Conference (Zurich, annual)
- Abundance 360 (Diamandis, annual mastermind)
- Don't Die Summit (Bryan Johnson)
- Life Itself (Mark Hyman)
- Health Optimization Summit (UK, annual)
- Biohackers World (multiple events)
- Wellness Real Estate Summit (GWS + allied)
- GWS Wellness Summit (Global Wellness Summit, annual)
- Hevolution Global Healthspan Summit (annual)
Publications and Communities
- Longevity.Technology — premier longevity industry news
- Lifespan.io — longevity advocacy and news
- LifeExtension Magazine — consumer supplement-oriented
- BeautyMatter — wellness/beauty business journalism
- Athletech News — fitness and wellness industry
- Fitt Insider — fitness industry newsletter
- Senior Housing News — longevity-adjacent real estate
- Global Wellness Summit — trend research and conference
- Global Wellness Institute — industry research foundation
- Reddit r/Biohackers, r/Longevity, r/Peptides, r/Nootropics — community epistemology
Education Platforms
- Institute for Functional Medicine (IFM) — physician certification
- Andrew Weil Center for Integrative Medicine (U of Arizona)
- Academy of Integrative Health and Medicine
- American Academy of Anti-Aging Medicine (A4M)
- American Board of Anti-Aging and Regenerative Medicine (ABAARM)
- Chopra Center / Chopra Global (Ayurveda)
- Kerala Ayurveda Academy
- Ayurvedic Institute (Vasant Lad)
- Huberman Lab content archive
- Attia's The Drive archive
Podcasts (Weekly Reach Estimates 2026)
- Joe Rogan Experience: 15M+ weekly
- Huberman Lab: 5M+ weekly
- Tim Ferriss Show: 2M+ weekly
- Lex Fridman Podcast: 2M+ weekly
- Peter Attia's The Drive: 1M+ weekly
- The Human Upgrade (Asprey): 200M+ cumulative downloads
- FoundMyFitness (Rhonda Patrick): millions cumulative
- Doctor's Farmacy (Hyman): millions
- Feel Better, Live More (Chatterjee): millions (UK/EU lead)
- Luke Storey Show, Ben Greenfield Life, Kevin Rose Show, Bulletproof Radio legacy
Appendix D — Peptide, Hormone, and Frontier Compound Reference
Peptides in Active Consumer Use (April 2026)
Recovery and Tissue Repair:
- BPC-157 (Body Protection Compound-157): tendon, ligament, GI tract, soft tissue
- TB-500 (Thymosin Beta-4): muscle/tendon recovery
- GHK-Cu (Copper tripeptide): skin repair, wound healing
Growth Hormone Secretagogues:
- Sermorelin: modest GH release, longest clinical track record
- CJC-1295 + Ipamorelin: more potent combination; pulsatile GH release
- Tesamorelin: FDA-approved for HIV-associated visceral fat; off-label longevity
- MK-677 (Ibutamoren): oral GH secretagogue, non-peptide
Immune and Longevity:
- Thymosin Alpha-1: immune modulation; approved in 35+ countries
- Epitalon / Epithalon: pineal-derived, longevity community favorite
- SS-31 (Elamipretide): mitochondrial peptide
Sexual Function:
- PT-141 (Bremelanotide): FDA-approved for HSDD in women
- Melanotan II: illicit market; tanning + sexual function
Weight Loss (GLP-1 family):
- Semaglutide: Ozempic/Wegovy (Novo Nordisk)
- Tirzepatide: Mounjaro/Zepbound (Eli Lilly)
- Retatrutide: triple agonist (Lilly, Phase 3)
- AOD-9604: historical fat-loss peptide
Cognitive/Nootropic:
- Semax, Selank: Russian-origin cognitive peptides
- Cerebrolysin: mixed peptide preparation
Regulatory Timeline Reference
- Sept 2023: FDA Category 2 restriction of 19 peptides
- Late 2024: BPC-157, TB-500, CJC-1295, Ipamorelin, etc. blocked from 503A/503B compounding
- Feb 27, 2026: RFK Jr. announced return of ~14 peptides to Category 1
- March 6, 2026: PeptideSciences.com voluntarily shut down
Pricing Reference (April 2026)
Licensed Compounded (with prescription):
- BPC-157: $150–$300/vial
- CJC-1295 + Ipamorelin: $200–$400/vial
- Sermorelin: $200–$350/vial
- Thymosin Alpha-1: $300–$500/vial
- Typical monthly protocol stack: $250–$1,000
Research Grade (no clinical support):
- BPC-157: $30–$120/vial (5mg, "not for human use")
- Other peptides: $25–$150/vial depending on molecule
Hormone Optimization Reference
Delivery Methods:
- Pellets: subcutaneous, quarterly (BioTE, EvexiPEL, SottoPelle networks)
- Injectables: weekly/biweekly (testosterone cypionate/enanthate)
- Creams: daily (compounded custom dosing)
- Troches/sublingual: daily (compounded)
Key Hormones:
- Testosterone: men and women (lower doses for women)
- Estradiol (E2): women
- Progesterone: women
- Pregnenolone, DHEA: both sexes
- Thyroid (T3, T4, NDT): both sexes as indicated
Regenerative Compounds Reference
- Exosomes: IV or injected; no FDA-approved exosome products; ~$1,500–$10,000/treatment
- Stem cells (MSCs): medical tourism required for most applications; Panama, Mexico, Bahamas, Colombia; $3,000–$60,000
- PRP (Platelet-Rich Plasma): autologous blood-derived; widely used in aesthetics and orthopedics
- Ozone therapy: MAH (major autohemotherapy); $200–$500/session; parallel economy; evidence debated
- NAD+ IV: $300–$1,000/session; widely available
- Rapamycin: off-label longevity use; prescription-required
- Metformin: off-label longevity use; TAME trial ongoing
- Fisetin, Quercetin, Dasatinib: senolytic compounds; intermittent-dose protocols
Appendix E — Source Synthesis and Methodology Notes
Primary Source Categories
Industry Research and Associations:
- Global Wellness Institute (GWI) — 2024 Global Wellness Economy Monitor
- Global Wellness Summit (GWS) — Future of Wellness 2026
- Consumer Healthcare Products Association (CHPA)
- Council for Responsible Nutrition (CRN)
- National Center for Complementary and Integrative Health (NCCIH) — 2022 Digest
- CDC — chronic disease prevalence data
- American Academy of Family Physicians (AAFP) — DPC data
- Hint Health — DPC growth survey
- Health Affairs — DPC practice growth research
Management Consulting / Strategic Research:
- McKinsey — Future of Wellness series (2020–2026)
- McKinsey — 2024 "Trends Defining the $1.8T Global Wellness Market"
- McKinsey — functional nutrition research
- McKinsey — women's wellness market analysis
- McKinsey — metabolic health revolution series
Consumer/Market Research:
- International Food Information Council (IFIC) — 2024 Food & Health Survey
- Circana, NIQ — consumer insights
- Rock Health — Consumer Digital Health Adoption Report
- SPINS — State of Supplements (Expo West 2025)
- Navigator Research — MAHA polling (2025–2026)
- KFF/Washington Post — MAHA parental polling (Oct 2025)
- Data for Progress / 314 Action — MAHA polling (April 2026)
- Morning Consult — MAHA tracking
Financial/Capital Research:
- Grand View Research, Mordor Intelligence, Precedence Research, Astute Analytica
- Future Market Insights, IBISWorld, Fortune Business Insights, SNS Insider
- Gabelli Funds — anti-aging research
- CB Insights — longevity venture data
- PitchBook — private market data
- New Market Pitch — longevity startup database
Primary and Direct Sources:
- FDA consumer alerts (exosomes, stem cells, compounding)
- eCFR (regulatory citations)
- Gallup Health and Healthcare Survey
- Edelman Trust Barometer
- Life Biosciences disclosures
- Fountain Life Executive Health Membership disclosures
- Neko Health, Function Health, Blueprint documentation
- Dave Asprey / Upgrade Labs materials
- Peter Diamandis's Abundance 360 / Longevity Platinum Trip materials
- Andrew Huberman's lab resources
Trade Press and Journalistic Coverage:
- BeautyMatter, Athletech News, Fitt Insider
- Senior Housing News
- CNBC, Fox Business, TIME, HBR
- The New York Times — Jasmine Sun's January 2026 Chinese peptides investigation
- SF Standard — stem cell tourism
- Fortune — Life Biosciences FDA approval coverage
- BioPharma Dive, Fierce Pharma — pharmaceutical industry trust data
- Wired, The Atlantic, New Yorker — cultural coverage
The Three-Lens Framework
Every category in this report is examined through three independent lenses:
- Commercial Trajectory — growth rate, operator count, capital, consumer adoption, pricing
- Regulatory Position — FDA, state regulation, enforcement, jurisdictional variation
- Scientific Evidence — peer-reviewed research, clinical trial stage, evidence strength
These lenses often disagree. A modality can be commercially booming, regulatorily restricted, and scientifically promising-but-incomplete. The reader is trusted to hold all three lenses simultaneously.
Where Sources Disagree
Where estimates diverge, this report presents both:
- U.S. wellness market: $2.1T (GWI, broad definition) vs. ~$500B (McKinsey, narrower consumer spend) — both methodologically defensible
- Chronic disease prevalence: 60% (Global Wellness Summit framing) vs. 76.4% (CDC 2023 data, 12 selected conditions, with 51.4% having multiple)
Temporal Frame
Present (April 2026) through 2030, with selected data points extending to 2034–2035 for capital planning and long-term strategic positioning. Historical context drawn from 2000–2025.
Limitations and Caveats
- Not medical advice. Nothing in this report should be interpreted as guidance for individual medical decisions.
- Not legal or regulatory advice. Specific regulatory questions require qualified counsel.
- Not investment advice. Valuations and trajectories discussed are market intelligence, not recommendations.
- Evolving data. The parallel economy is moving rapidly; specific data points may shift quarterly. The structural analysis is designed to be more durable than specific numerical claims.
- Selection bias. This report emphasizes operators and figures judged strategically significant. Many credible practitioners and companies are not named here simply for space.
- U.S. focus. International context provided, but the primary lens is U.S. market dynamics.
Intended Use
This report is a strategic intelligence document. It is designed to:
- Inform strategic positioning decisions for operators, investors, and advisors
- Provide briefing material for executive and client conversations
- Serve as a reference document for ongoing work in the category
- Support downstream conversion into Word, PowerPoint, web, and other formats
The document is not designed to be read linearly. Sections can be consumed independently, and the table of contents is structured to support topic-specific deep dives.
Document Evolution
- Version 1.0 (Initial delivery): ~13,300 words, 13 sections
- Version 2.0 (Addendum integration): not finalized; superseded
- Version 3.0 (This edition — The Definitive Edition): ~40,000+ words, 9 parts, 59 sections, extensive people profiles, multi-format export-ready structure
Multi-Format Conversion Notes
This markdown source is designed to convert cleanly to:
- Microsoft Word (.docx): clean H1/H2/H3 hierarchy supports automatic style mapping; tables render natively; mini-profile blocks convert to card layouts
- PowerPoint (.pptx): section-opening thesis lines can become slide titles; mini-profile blocks can become cards or slide grids; tables can be slide-embedded
- Website (HTML): semantic heading structure supports automatic navigation; tables responsive; profile blocks convert to card layouts in CSS
- PDF: standard markdown-to-PDF pipelines render professionally
Final Attribution
Document author: Claude (Anthropic), in strategic advisory collaboration with Mr. Deven, Life Kitchen Studios.
Research synthesis: April 2026, drawing on sources published through April 2026.
Publication context: Strategic market intelligence for Life Kitchen Studios' vCAIO consulting practice, executive briefings, client advisory engagements, and potential public-facing content development (Hippocrates Wellness strategic brief, FutureFast.ai article, Thrivemore Technology Advisors integration, Alys Beach thesis work, additional client applications).
Copyright and use: This document is produced as proprietary research for Life Kitchen Studios. Derivative formats (Word, PowerPoint, website, pitch decks, executive briefings) may be developed for specific client applications.
End of Appendices. End of Report.